Corresponding Author: David L. Swerdlow, MD, Clinical Epidemiology Lead, Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 (david.swerdlow@pfizer.com).
Published Online: February 11, 2020. doi:10.1001/jama.2020.1960
Conflict of Interest Disclosures: Dr Swerdlow reports owning stock and stock options in Pfizer Inc. Dr Swerdlow also reports providing a one-time consultation consisting of an overview of SARS and MERS epidemiology to GLG Consulting and receiving an honorarium. Dr Finelli reports owning stock in Merck and Co.
Funding/Support: Pfizer Inc provided salary support for Dr Swerdlow.
Role of the Funder/Sponsor: Pfizer Inc reviewed the manuscript and approved the decision to submit the manuscript for publication.
1.Swerdlow
DL, Finelli
L, Bridges
CB. 2009 H1N1 influenza pandemic: field and epidemiologic investigations in the United States at the start of the first pandemic of the 21st century.
Clin Infect Dis. 2011;52(suppl 1):S1-S3. doi:
10.1093/cid/ciq005PubMedGoogle ScholarCrossref 2.Balcan
D, Hu
H, Goncalves
B,
et al. Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility.
BMC Medicine. 2009;7(45). doi:
10.1186/1741-7015-7-45 8.Wang
D, Hu
B, Hu
C,
et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China.
JAMA. Published online February 7, 2020. doi:
10.1001/jama.2020.1585PubMedGoogle Scholar